Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | PLAU | P00749 | 2/20 | 0.55 |
| ▸ | TCF4 | P15884 | 2/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315174 | 0.89 | MAPT (0.80) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL9225092 | 0.87 | ALDH1A1 (0.59) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL5925553 | 0.83 | MAPT (0.72) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL1832364 | 0.83 | MAPT (0.72) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL1279147 | 0.82 | PLAU (0.72) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL25413790 | 0.82 | MAPT (0.70) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL15772389 | 0.82 | MAPT (0.70) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL6977966 | 0.82 | MAPT (0.70) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL21761420 | 0.81 | ALDH1A1 (0.69) | MAPTALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL5040416 | 0.80 | GAA (0.69) | MAPTALDH1A1TSHRSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250325-B1 | PHENANTHRIDINE-N-OXIDES | NYCOMED GMBH (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-6630483-B2 | Phenanthridine-N-oxides | ALTANA PHARMA AG (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20030105123-A1 | For therapy of respiratory system disorders | ALTANA PHARMA AG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1250325-A1 | PHENANTHRIDINE-N-OXIDES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| EP-0889886-B1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | ALTANA PHARMA AG (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001051470-A1 | PHENANTHRIDINE-N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
| US-6127378-A | A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-03 | — | — | US | disclosed |
| EP-0889886-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997035854-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105123-A1 | For therapy of respiratory system disorders | CHRM3, CYP11B1, CYP11B2 | MAPT 4639/4885ALDH1A1 1029/4885TSHR 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.